Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML ... On the other hand, NPM1 mutation also was noted as a favorable prognostic factor.

evaluated the safety and efficacy of its experimental drug revumenib in adults with relapsed or refractory mutant NPM1 AML, a difficult-to-treat form of AML with specific genetic mutations.

The company's focus on targeted therapies for specific genetic mutations in AML, such as KMT2A rearrangements and NPM1 mutations, could provide a competitive edge in a market that is increasingly ...

“More than half of AML patients with an NPM1 mutation will relapse with poor survival outcomes ii, making it a significant area of unmet medical need in the frontline setting,” said Takeyoshi ...

AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Responses to TUS were also observed in those with prior-VEN and prior-FLT3 inhibitor (FLT3i) therapies ...